tiprankstipranks
Advertisement
Advertisement

HIND Stock Latest News

Vyome announces CNIPA granted patent covering formula related to besifloxacin
The FlyVyome announces CNIPA granted patent covering formula related to besifloxacin
8d ago
HIND
Vyome reports Q1 EPS (15c) vs. ($761.59) last year
PremiumThe Fly
Vyome reports Q1 EPS (15c) vs. ($761.59) last year
1M ago
HIND
Vyome signs exclusive license agreement with Impetis
PremiumThe Fly
Vyome signs exclusive license agreement with Impetis
2M ago
HIND
Vyome initiated with a Buy at Litchfield Hills
PremiumThe Fly
Vyome initiated with a Buy at Litchfield Hills
2M ago
HIND
Vyome Holdings Shareholders Tighten Capital Structure at Meeting
PremiumCompany Announcements
Vyome Holdings Shareholders Tighten Capital Structure at Meeting
2M ago
8K
HIND
Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market
PremiumRatingsVyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market
3M ago
HIND
Vyome Holdings presents Phase 2 study results on VT-1953
Premium
The Fly
Vyome Holdings presents Phase 2 study results on VT-1953
3M ago
HIND
Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026
Premium
The Fly
Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026
3M ago
HIND
Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year
PremiumThe Fly
Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year
3M ago
HIND
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics
PremiumCompany Announcements
Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics
4M ago
8K
HIND
Vyome Holdings publishes preclinical VT-1908 data
PremiumThe Fly
Vyome Holdings publishes preclinical VT-1908 data
5M ago
HIND
Vyome Reports Positive Phase 2 Data for VT-1953 Gel
PremiumCompany Announcements
Vyome Reports Positive Phase 2 Data for VT-1953 Gel
5M ago
8K
HIND
Vyome Holdings funds budget for VT-1953 study
PremiumThe FlyVyome Holdings funds budget for VT-1953 study
5M ago
HIND
Vyome Holdings Highlights VT-1953 Market Potential Analysis
Premium
Company Announcements
Vyome Holdings Highlights VT-1953 Market Potential Analysis
5M ago
8K
HIND
Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition
Premium
Company Announcements
Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition
7M ago
8K
HIND
Vyome Holdings: Promising Advancements in MFW Treatment and Strategic Market Positioning Drive Buy Rating
PremiumRatings
Vyome Holdings: Promising Advancements in MFW Treatment and Strategic Market Positioning Drive Buy Rating
7M ago
HIND
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints
PremiumThe Fly
Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints
7M ago
HIND
Vyome Holdings Inc. Reports Post-Merger Financials
PremiumCompany Announcements
Vyome Holdings Inc. Reports Post-Merger Financials
8M ago
HIND
Vyome Holdings: Buy Rating Backed by Promising Pipeline and Strategic Growth Potential
PremiumRatings
Vyome Holdings: Buy Rating Backed by Promising Pipeline and Strategic Growth Potential
8M ago
HIND
Vyome Holdings files to sell 610K shares of common stock for holders
PremiumThe FlyVyome Holdings files to sell 610K shares of common stock for holders
8M ago
HIND
Vyome Holdings Elects Directors at Annual Meeting
Premium
Company Announcements
Vyome Holdings Elects Directors at Annual Meeting
8M ago
8K
HIND
Vyome Holdings Acquires AI Startup Oculo, Inc.
Premium
Company Announcements
Vyome Holdings Acquires AI Startup Oculo, Inc.
9M ago
8K
HIND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >